Orion (ORINY) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Orion (OTCMKTS:ORINY) from a strong sell rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “

How to Become a New Pot Stock Millionaire

Shares of Orion stock opened at $15.10 on Tuesday. Orion has a 52-week low of $15.06 and a 52-week high of $21.17. The company has a market capitalization of $4,265.96, a PE ratio of 15.41, a PEG ratio of 19.26 and a beta of 0.43.

ILLEGAL ACTIVITY NOTICE: “Orion (ORINY) Upgraded by Zacks Investment Research to “Hold”” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://weekherald.com/2018/04/18/orion-oriny-upgraded-by-zacks-investment-research-to-hold.html.

About Orion

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.

Get a free copy of the Zacks research report on Orion (ORINY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply